Human Genome Sciences Initiates Phase 2 Clinical Trial of Albuferon(TM) for the
- Human Genome Sciences Initiates Phase 2 Clinical Trial of Albuferon(TM) for the Treatment of Chronic Hepatitis C
Wednesday May 26, 8:20 am ET
ROCKVILLE, Md., May 26 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - News) announced today that it has begun dosing patients in a Phase 2 clinical trial of Albuferon(TM) (albumin-interferon alpha) in patients with chronic hepatitis C who are naive to interferon-alpha treatments.
[Non-text portions of this message have been removed]